Gamida Cell Ltd. (NASDAQ: GMDA) stock jumped 13.36% on Friday to $2.46 against a previous-day closing price of $2.17. With 1.65 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.36 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.5500 whereas the lowest price it dropped to was $2.0100. The 52-week range on GMDA shows that it touched its highest point at $5.91 and its lowest point at $1.48 during that stretch. It currently has a 1-year price target of $14.40. Beta for the stock currently stands at 1.70.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GMDA was up-trending over the past week, with a rise of 43.02%, but this was up by 32.26% over a month. Three-month performance surged to 6.03% while six-month performance fell -24.54%. The stock lost -55.52% in the past year, while it has lost -3.15% so far this year. A look at the trailing 12-month EPS for GMDA yields -1.55 with Next year EPS estimates of -1.04. For the next quarter, that number is -0.29. This implies an EPS growth rate of -7.60% for this year and 16.80% for next year.
Float and Shares Shorts:
At present, 59.47 million GMDA shares are outstanding with a float of 41.91 million shares on hand for trading. On Jul 14, 2022, short shares totaled 2.72 million, which was 4.53% higher than short shares on Jun 14, 2022. In addition to Dr. Julian Adams Ph.D. as the firm’s CEO & Director, Mr. Shai Lankry CPA, M.B.A. serves as its Chief Financial Officer.
Through their ownership of 29.32% of GMDA’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.38% of GMDA, in contrast to 17.33% held by mutual funds. Shares owned by individuals account for 0.66%. As the largest shareholder in GMDA with 7.65% of the stake, Fidelity Management & Research Co holds 4,587,704 shares worth 4,587,704. A second-largest stockholder of GMDA, Federated Global Investment Manag, holds 2,539,164 shares, controlling over 4.24% of the firm’s shares. Rock Springs Capital Management L is the third largest shareholder in GMDA, holding 2,154,300 shares or 3.59% stake. With a 5.96% stake in GMDA, the Federated Hermes Kaufmann Fund is the largest stakeholder. A total of 3,570,815 shares are owned by the mutual fund manager. The Fidelity VIP – Growth Portfolio, which owns about 2.79% of GMDA stock, is the second-largest Mutual Fund holder. It holds 1,674,200 shares valued at 2.96 million. Fidelity Capital Appreciation Fun holds 1.87% of the stake in GMDA, owning 1,122,170 shares worth 1.99 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GMDA since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GMDA analysts setting a high price target of $22.00 and a low target of $6.00, the average target price over the next 12 months is $14.40. Based on these targets, GMDA could surge 794.31% to reach the target high and rise by 143.9% to reach the target low. Reaching the average price target will result in a growth of 485.37% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. GMDA will report FY 2022 earnings on 02/28/2023. Analysts have provided yearly estimates in a range of -$1.09 being high and -$1.28 being low. For GMDA, this leads to a yearly average estimate of -$1.19. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Gamida Cell Ltd. reported -$0.34 EPS against a consensus estimate of -$0.34. The surprise factor in the prior quarter was -$0.12. Based on analyst estimates, the high estimate for the next quarter is -$0.27 and the low estimate is -$0.32. The average estimate for the next quarter is thus -$0.29.
Summary of Insider Activity:
Insiders traded GMDA stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 4,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 6 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 169,800 while 0 shares were sold.